Bullish
Merck & Co., Inc. announced that the European Commission has approved ENFLONSIA (clesrovimab) to prevent respiratory syncytial virus (RSV) lower respi...
Bullish
Merck & Co Inc. has provided grant funding through the National Comprehensive Cancer Network (NCCN) to four research teams to improve lung cancer scre...
Neutral
This report analyzes Merck & Co., Inc.'s business model, particularly its reliance on the blockbuster cancer drug Keytruda, in light of its impending ...
Neutral
MASTERINVEST Kapitalanlage GmbH boosted its stake in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 25.1% during the fourth quarter, Holdings...
Neutral
Merck & Co Inc (MRK) saw its shares rise 3.1% to $119.07, but GuruFocus indicates the stock is 1.2% overvalued with a GF Value™ of $117.69. Despite a ...
Neutral
Merck & Co., Inc. is a pharmaceutical powerhouse heavily reliant on its blockbuster oncology drug, Keytruda, which faces patent expiry around 2028. Th...
Neutral
This report analyzes Merck & Co. Inc.'s business model, competitive advantages, and future prospects, particularly focusing on its oncology and vaccin...
Neutral
Merck & Co., Inc. relies heavily on its blockbuster cancer drug Keytruda, which accounts for over 40% of its sales, raising questions about sustained ...